Tumor DDR1 acts as a key factor during the desmoplastic response surrounding hepatic colorectal metastasis. Hepatic sinusoidal cell-derived soluble factors stimulate tumor DDR1 activation. DDR1 modulates matrix remodeling to promote metastasis in the liver through the interaction with hepatic stromal cells, specifically liver sinusoidal endothelial cells and hepatic stellate cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1152/ajpgi.00078.2021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications.
Exp Hematol Oncol
January 2025
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430300, China.
Article Synopsis
- Immune checkpoint therapies have revolutionized cancer treatment but face challenges like low response rates and drug resistance, highlighting the need for a better understanding of the tumor microenvironment (TME).
- Recent studies show that biomechanical forces within the TME significantly impact immune responses and tumor progression, indicating that manipulating these forces could enhance immune activation against tumors.
- The review discusses key biomechanical mechanisms, the role of the extracellular matrix, and potential clinical applications, aiming to provide insights for discovering new therapeutic targets.
DDR1 in pancreatic adenocarcinoma: unraveling the mechanisms of immune exclusion.
Scand J Gastroenterol
December 2024
Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, China.
Background: Pancreatic adenocarcinoma (PAAD) is a deadly cancer marked by extensive collagen deposition and limited response to immunotherapy. Discoidin domain receptor1 (DDR1), part of the transmembrane receptor tyrosine kinase family, is linked to inflammation regulation and immune cell infiltration. However, its role in controlling cytokines and chemokines in the microenvironment of PAAD is still unclear.
View Article and Find Full Text PDFThe role of DDR1 in cancer and the progress of its selective inhibitors.
Bioorg Chem
December 2024
Department of pharmacy, Nanjing Drum Tower Hospital, Nanjing, Jiangsu Province 210008, China. Electronic address:
Discoidin domain receptor 1 (DDR1) is a member of the receptor tyrosine kinase superfamily, which mainly activates downstream signaling pathways through binding to collagen. The abnormal expression of DDR1 is closely related to the occurrence and development of various tumors, and it is one of the potential targets for molecular targeted therapy. At present, specific antibodies and selective small molecule inhibitors against DDR1 have been approved for Phase I clinical trials.
View Article and Find Full Text PDFInhibition of discoidin domain receptor 1 as a new therapeutic strategy for osteosarcoma.
FASEB J
December 2024
Sarcoma Biology Laboratory, Department of Orthopedic Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Osteosarcoma is the most common type of bone cancer. Some patients eventually develop recurrent or metastatic diseases and treatment options are extremely limited. Discoidin domain receptor 1 (DDR1) is a unique collagen-activated tyrosine kinase that participates in various human diseases, including cancer.
View Article and Find Full Text PDFTFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer.
Cancer Lett
February 2025
Department of Biochemistry and Molecular Medicine, GWU Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC, 20037, USA. Electronic address:
Breast cancer is the predominant malignancy with the majority of cases are characterized as HR+/HER2-subtype. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have shown remarkable efficacy in treating this subtype when combined with endocrine therapy, the development of resistance to these inhibitors remains a significant clinical obstacle. Hence, there is an urgent need to explore innovative therapies and decipher the underlying mechanisms of resistance to CDK4/6i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!